441 related articles for article (PubMed ID: 34359598)
1. Triple Negative Breast Cancer: A Mountain Yet to Be Scaled Despite the Triumphs.
Wu Q; Siddharth S; Sharma D
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359598
[TBL] [Abstract][Full Text] [Related]
2. The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.
He L; Wick N; Germans SK; Peng Y
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944829
[TBL] [Abstract][Full Text] [Related]
3. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
4. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer.
Fatima I; El-Ayachi I; Taotao L; Lillo MA; Krutilina RI; Seagroves TN; Radaszkiewicz TW; Hutnan M; Bryja V; Krum SA; Rivas F; Miranda-Carboni GA
PLoS One; 2017; 12(12):e0189864. PubMed ID: 29281678
[TBL] [Abstract][Full Text] [Related]
5. Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistance.
Jalalirad M; Haddad TC; Salisbury JL; Radisky D; Zhang M; Schroeder M; Tuma A; Leof E; Carter JM; Degnim AC; Boughey JC; Sarkaria J; Yu J; Wang L; Liu MC; Zammataro L; Malatino L; Galanis E; Ingle JN; Goetz MP; D'Assoro AB
Oncogene; 2021 Apr; 40(14):2509-2523. PubMed ID: 33674749
[TBL] [Abstract][Full Text] [Related]
6. Current therapeutic approaches and promising perspectives of using bioengineered peptides in fighting chemoresistance in triple-negative breast cancer.
Azari M; Bahreini F; Uversky VN; Rezaei N
Biochem Pharmacol; 2023 Apr; 210():115459. PubMed ID: 36813121
[TBL] [Abstract][Full Text] [Related]
7. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
8. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Yagata H; Kajiura Y; Yamauchi H
Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
[TBL] [Abstract][Full Text] [Related]
9. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Reprogramming in Triple-Negative Breast Cancer.
Sun X; Wang M; Wang M; Yu X; Guo J; Sun T; Li X; Yao L; Dong H; Xu Y
Front Oncol; 2020; 10():428. PubMed ID: 32296646
[TBL] [Abstract][Full Text] [Related]
11. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
12. Decoding gene regulatory circuitry underlying TNBC chemoresistance reveals biomarkers for therapy response and therapeutic targets.
Lusby R; Zhang Z; Mahesh A; Tiwari VK
NPJ Precis Oncol; 2024 Mar; 8(1):64. PubMed ID: 38472332
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
14. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
15. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer.
Assidicky R; Tokat UM; Tarman IO; Saatci O; Ersan PG; Raza U; Ogul H; Riazalhosseini Y; Can T; Sahin O
Breast Cancer Res Treat; 2022 Jun; 193(2):331-348. PubMed ID: 35338412
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC.
Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586
[TBL] [Abstract][Full Text] [Related]
18. Triple negative breast cancer: looking for the missing link between biology and treatments.
Palma G; Frasci G; Chirico A; Esposito E; Siani C; Saturnino C; Arra C; Ciliberto G; Giordano A; D'Aiuto M
Oncotarget; 2015 Sep; 6(29):26560-74. PubMed ID: 26387133
[TBL] [Abstract][Full Text] [Related]
19. Zinc transporter LIV1: A promising cell surface target for triple negative breast cancer.
Saravanan R; Balasubramanian V; Swaroop Balamurugan SS; Ezhil I; Afnaan Z; John J; Sundaram S; Gouthaman S; Pakala SB; Rayala SK; Venkatraman G
J Cell Physiol; 2022 Nov; 237(11):4132-4156. PubMed ID: 36181695
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of Tumor Metabolic Reprogramming in Triple-Negative Breast Cancer.
Munkácsy G; Santarpia L; Győrffy B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
